Diabetes, cardiovascular disease, and health care use in people with and without schizophrenia

European Psychiatry

Volumn 26, Issue 5, 2011, Pages 327-332

  Bresee, L C ^a,b   Majumdar, S R ^a,b   Patten, S B ^c,d   Johnson, J A ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INSTITUTE OF HEALTH ECONOMICS   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Epidemiology; Miscellaneous; Quality of care; Schizophrenia

Indexed keywords

ADULT; ARTICLE; CANADIAN COMMUNITY HEALTH SURVEY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EDUCATIONAL STATUS; FEMALE; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HEALTH SURVEY; HEART DISEASE; HOSPITALIZATION; HUMAN; HYPERTENSION; INCOME; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RISK MANAGEMENT; SCHIZOPHRENIA; SINGLE MAN; STROKE;

ADULT; AGED; CANADA; CARDIOVASCULAR DISEASES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DELIVERY OF HEALTH CARE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; QUALITY OF HEALTH CARE; RISK FACTORS; SCHIZOPHRENIA;

EID: 79960447705     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2010.05.003     Document Type: Article

References (39)

1. Allison D.B., Fontaine K.R., Heo M., et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999, 60:215-220.
2. Balf G., Stewart T.D., Whitehead R., Baker R.A. Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective. Prim Care Companion J Clin Psychiatry 2008, 10:15-24.
3. Baliunas D.O., Taylor B.J., Irving H., et al. Alcohol as a risk factor for type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 2009, 32:2123-2132.
4. Bresee L.C., Majumdar S.R., Patten S.B., Johnson J.A. Burden of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010, 117:75-82.
5. Bushe C. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry 2004, 184:S67-S71.
6. Canadian Council on Social Development: Available at: http://www.ccsd.ca/factsheets/fs_lico05_bt.htm. [Accessed February 24, 2010].
7. Canadian Psychiatric Association Working Group. Clinical Practice Guidelines: treatment of Schizophrenia. Can J Psychiatry 2005;50(Suppl. 1):1S-56S.
8. Citrome L.L., Jaffe A.B. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 2003, 37:1849-1857.
9. Cohn T., Prud'homme D., Streiner D., Kameh H., Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004, 49:753-760.
10. Curkendall S.M., Mo J., Glasser D.B., Stang M.R., Jones J.K. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 2004, 65:715-720.
11. De Hert M., Dekker J.M., Wood D., Kahl K.G., Holt R.I.G., Moller H.J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009, 24:412-424.
12. Delgado-Rodriguez M., Bias L.J. J Epidemiol Community Health 2004, 58:635-641.
13. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002;346:393-403.
14. Dixon L., Weiden P., Delahanty J., et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000, 26:903-912.
15. Druss B.G., Bradford D., Rosenheck R.A., Radford M.J., Krumholz H.M. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001, 58:565-572.
16. Eaker E.D., Sullivan L.M., Kelly-Hayes M., D'Agostino R.B., Benjamin E.J. Marital status, marital strain, and risk of coronary heart disease or total mortality: the Framingham Offspring Study. Psychosom Med 2007, 69:509-513.
17. Field A.E., Coakley E.H., Must A., et al. Impact of overweight on the risk of developing chronic diseases during a 10-year period. Arch Intern Med 2001, 161:1581-1586.
18. Gianfrancesco F., White R., Wang R.H., Nasrallah H.A. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003, 23:328-335.
19. Goldner E.M., Hsu L., Waraich P., Somers J.M. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 2002, 47:833-843.
20. Haupt D.W., Rosenblatt L.C., Kim E., Baker R.A., Whitehead R., Newcomer J.W. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009, 166:345-353.
21. Health Canada. Canadian Guidelines for Body Weight Classification in Adults. Ottawa, ON: Health Canada; 2003. Publication H49-179/2003E. Available at: http://www.hc-sc.gc.ca/fn-an/alt_formats/hpfb-dgpsa/pdf/nutrition/weight_book-livres_des_poids-eng.pdf. [Accessed February 24, 2010].
22. Hosmer D.W., Lemeshow S Applied Logistic Regression 2000, John Wiley & Sons, Inc, Hoboken, NJ. 2nd ed.
23. Hsu C., Ried L.D., Bengtson M.A., Garman P.M., McConkey J.R., Rahnavard F. Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population. J Am Pharm Assoc 2008, 48:393-400.
24. Johnson J.A., Vermeulen S.U. Epidemiological trends of diabetes in Alberta. Alberta Diabetes Atlas 2007 2007, 11-24. Institute of Health Economics, Edmon, Alberta.
25. Kaplan G.A., Keil J.E. Socioeconomic factors and cardiovascular disease: a review of the literature. Circulation 1993, 88:1973-1998.
26. Kisely S., Smith M., Lawrence D., Cox M., Campbell L.A., Maaten S. Inequitable access for mentally ill patients to some medically necessary procedures. CMAJ 2007, 176:779-784.
27. Lambert B.L., Cunningham F.E., Miller D.R., Dalack G.W., Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in Veterans Health Administration patients with schizophrenia. Am J Epidemiol 2006, 164:672-681.
28. Maddigan S.L., Feeny D.H., Majumdar S.R., Farris K.B., Johnson J.A. Health Utilities Index mark 3 demonstrated construct validity in a population-based sample with type 2 diabetes. J Clin Epidemiol 2006, 59:472-477.
29. McEvoy J.P., Meyer J.M., Goff D.C., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80:19-32.
30. Morrato E.H., Newcomer J.W., Allen R.R., Valuck R.J. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry 2008, 69:316-322.
31. Nasrallah H.A., Meyer J.M., Goff D.C., et al. Low rates of treatment for hypertension, dyslipidemia, and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006, 86:15-22.
32. Osborn D.P.J., Levy G., Nazareth I., Petersen I., Islam A., King M.B. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007, 64:242-249.
33. Statistics Canada. Canadian Community Health Survey (CCHS) cycle 3.1. Available at: http://www.statcan.gc.ca/cgi-bin/imdb/p2SV.pl?Function=getSurvey&SurvId=3226&SurvVer=0&InstaId=15282&InstaVer=3&SDDS=3226&lang=en&db=imdb&adm=8&dis=2. [Accessed February 24, 2010].
34. Statistics Canada. Canadian Community Health Survey (CCHS) response rates. Available at: http://www.statcan.gc.ca/imdb-bmdi/document/3226_D19_T9_V1_B.pdf. [Accessed February 24, 2010].
35. Statistics Canada. Canadian Community Health Survey (CCHS) cycle 3.1: Integrated derived variable (DV) and grouped variable specifications. Available at: http://webapps6.ucalgary.ca/~landru/adc/cchs/2005/derive.pdf. [Accessed May 12, 2010].
36. Supina A.L., Patten S.B. Self-reported diagnoses of schizophrenia and psychotic disorders may be valuable for monitoring and surveillance. Can J Psychiatry 2006, 51:256-259.
37. Voruganti L.P., Punthakee Z., Van Lieshout R.J., MacCrimmon D., Parker G., Awad A.G., et al. Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-south Ontario (DiSCO) study. Schizophr Res 2007, 96:215-222.
38. Willi C., Bodenmann P., Ghali W.A., Faris P.D., Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007, 298:2654-2664.
39. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.